ACL 3.20% $2.42 australian clinical labs limited

potential catakyst to rocket soon, page-12

  1. 270 Posts.
    lightbulb Created with Sketch. 20
    I think everyone knows but fails to admit that there isn’t much share price action due to unsustainable revenue or earnings growth for next 10 years. At least what institutional investors might think.

    jobkeeper is gone.
    we are approaching endemic therefore government covid subsidies will be cut down or eliminated.
    everyone knows that these earnings were just a temporary boost by government for providing covid 19 testing rebates.

    Also company decided to do IPO at most convenient environment for it’s share price therefore for what most think “next years earnings will drive share price growth”
    it’s been factored in last year already.

    not a holder, or shorter. Was thinking going long considering recent financial performance but after digging I think they should prove themselves as healthy company asides from temporary cash flush from Commonwealth
 
watchlist Created with Sketch. Add ACL (ASX) to my watchlist
(20min delay)
Last
$2.42
Change
-0.080(3.20%)
Mkt cap ! $492.4M
Open High Low Value Volume
$2.50 $2.53 $2.40 $976.6K 399.7K

Buyers (Bids)

No. Vol. Price($)
11 10736 $2.41
 

Sellers (Offers)

Price($) Vol. No.
$2.42 2906 4
View Market Depth
Last trade - 13.58pm 09/07/2024 (20 minute delay) ?
ACL (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.